Chicago Equity Partners LLC boosted its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 60.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,299 shares of the medical equipment provider’s stock after purchasing an additional 3,864 shares during the quarter. Chicago Equity Partners LLC’s holdings in ABIOMED were worth $4,213,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ABMD. Harvest Fund Management Co. Ltd acquired a new stake in ABIOMED in the first quarter worth $108,000. WealthTrust Fairport LLC acquired a new stake in ABIOMED in the first quarter worth $145,000. Cerebellum GP LLC acquired a new stake in ABIOMED in the second quarter worth $151,000. Dupont Capital Management Corp acquired a new stake in ABIOMED in the first quarter worth $161,000. Finally, NewSquare Capital LLC acquired a new stake in ABIOMED in the second quarter worth $186,000. Institutional investors and hedge funds own 86.46% of the company’s stock.

ABIOMED stock opened at $408.58 on Friday. ABIOMED, Inc. has a 1-year low of $144.01 and a 1-year high of $450.93. The firm has a market capitalization of $17.32 billion, a price-to-earnings ratio of 166.77, a price-to-earnings-growth ratio of 4.14 and a beta of -0.02.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, July 26th. The medical equipment provider reported $1.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.80 by $1.15. ABIOMED had a net margin of 25.71% and a return on equity of 18.91%. The firm had revenue of $180.01 million for the quarter, compared to analyst estimates of $173.87 million. During the same period last year, the firm earned $0.82 earnings per share. The business’s quarterly revenue was up 35.9% compared to the same quarter last year. equities research analysts anticipate that ABIOMED, Inc. will post 3.45 EPS for the current fiscal year.

In other ABIOMED news, COO David M. Weber sold 46,500 shares of the firm’s stock in a transaction on Monday, June 18th. The shares were sold at an average price of $442.63, for a total value of $20,582,295.00. Following the transaction, the chief operating officer now directly owns 189,657 shares of the company’s stock, valued at $83,947,877.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Michael R. Minogue sold 105,000 shares of the firm’s stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $439.69, for a total transaction of $46,167,450.00. Following the transaction, the chairman now directly owns 481,150 shares in the company, valued at $211,556,843.50. The disclosure for this sale can be found here. Insiders sold 170,782 shares of company stock worth $73,628,984 over the last ninety days. Insiders own 3.50% of the company’s stock.

A number of equities research analysts have commented on ABMD shares. Zacks Investment Research upgraded shares of ABIOMED from a “hold” rating to a “buy” rating and set a $338.00 price target for the company in a report on Thursday, May 3rd. Piper Jaffray Companies raised their price target on shares of ABIOMED to $360.00 and gave the stock an “overweight” rating in a report on Thursday, May 3rd. ValuEngine upgraded shares of ABIOMED from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 3rd. Jefferies Financial Group raised their price objective on shares of ABIOMED to $460.00 and gave the company a “buy” rating in a research note on Tuesday, May 29th. Finally, BidaskClub lowered shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. ABIOMED presently has an average rating of “Buy” and a consensus target price of $374.88.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Story: Understanding Price to Earnings Ratio (PE)

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.